Description: Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease. These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Trevi is currently conducting a Phase 2b/3 clinical trial of nalbuphine ER, referred to as the PRISM trial, in patients with severe pruritus associated with prurigo nodularis. Founded in 2011, Trevi Therapeutics is headquartered in New Haven, CT.
Home Page: www.trevitherapeutics.com
TRVI Technical Analysis
195 Church Street
New Haven,
CT
06510
United States
Phone:
203 304 2499
Officers
| Name | Title |
|---|---|
| Ms. Jennifer L. Good | Co-Founder, CEO, Pres & Director |
| Dr. Thomas R. Sciascia M.D. | Co-Founder & Chief Science Officer |
| Ms. Lisa Delfini | Chief Financial Officer |
| Mr. Christopher Galletta | Controller & Chief Accounting Officer |
| Katie McManus | Communications Mang. |
| Mr. Farrell Simon Pharm.D. | Sr. VP and Head of Commercial & Strategy |
| Dr. David J. Clark A.F.P.M., M.D., M.R.C.P. | Chief Medical Officer |
| Ms. Danine Summers | VP of Medical Affairs |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.2704 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2019-05-07 |
| Fiscal Year End: | December |
| Full Time Employees: | 23 |